Ginkgo Bioworks Holdings, Inc. Class A (DNA)

Ginkgo Bioworks Holdings, Inc. stock has experienced volatility in the past six months. The stock's price target decreased by 11.11% to $10.88 in November 2025, coinciding with a widened Q3 2025 loss. Partnerships with Agricen and Carnegie-Mellon University were announced in December 2025 and January 2026. A COO transition and operational leadership changes were also announced, effective January 2026. The stock has shown a 6-month change of -1.59% as of January 14, 2026.

Ginkgo Bioworks Holdings, Inc. has been operating in a challenging demand environment, which has contributed to a lack of growth in recent years. This weak demand is largely attributed to the rapid rise in interest rates since 2022, which has also put pressure on funding for academic customers. While biopharma spending has been soft, it has been one of the few brighter spots for Ginkgo. The company's industrial and consumer businesses have experienced a near halt in demand. There is no explicit information indicating a distinct seasonal pattern in the demand for Ginkgo's products and services; rather, the demand environment is described as generally weak due to broader economic factors.

Ginkgo Bioworks Holdings, Inc. is an American biotechnology company specializing in cell programming, founded in 2008 with the mission to make biology easier to engineer. The company operates within the Healthcare sector, offering services through its Cell Engineering and Biosecurity segments. The Cell Engineering segment provides research and development solutions, while the Biosecurity segment offers biomonitoring and bioinformatics support services.

Ginkgo Bioworks Holdings, Inc. is headquartered in Boston, Massachusetts, and develops its cell programming platform primarily in the United States. In addition to its Boston headquarters and facilities in Cambridge, Massachusetts, the company acquired property for a new laboratory building in the Raymond L Flynn Marine Park in 2020. Ginkgo also expanded its footprint by acquiring Bayer's Biologics Research & Development site in West Sacramento in October 2022.

Ginkgo Bioworks' brand reputation has faced challenges in the past year, particularly concerning its financial performance and business model. Articles have highlighted concerns such as declining core revenue, high cash burn, and disappointing revenue guidance. The company's stock has been described as volatile and has seen a significant decline. In October and November 2021, Ginkgo faced fraud allegations, including accusations of embellishing revenue through related-party transactions, which prompted an inquiry by the United States Department of Justice and a shareholder lawsuit.

Ginkgo Bioworks Holdings, Inc. has a diverse ownership structure, with institutional investors holding approximately 15.72% to 45.26% of the company's stock, insiders holding around 0.99% to 3.47%, and retail investors holding the remainder. Major institutional owners include Viking Global Investors Lp, BlackRock, Inc., and Baillie Gifford & Co. Key individual and insider owners include Cascade Investment LLC, Eagle Equity Partners III LLC, and co-founders Barry Canton, Reshma P. Shetty, Marijn E. Dekkers, and Jason R. Kelly.